Zydus Lifesciences Limited (BOM:532321)

Market Cap	920.75B
Revenue (ttm)	244.94B
Net Income (ttm)	49.20B
Shares Out	n/a
EPS (ttm)	48.89
PE Ratio	18.72
Forward PE	21.08
Dividend	11.00 (1.22%)
Ex-Dividend Date	Jul 25, 2025

Volume	20,342
Average Volume	17,538
Open	918.00
Previous Close	914.65
Day's Range	907.25 - 920.70
52-Week Range	797.05 - 1,059.00
Beta	n/a
RSI	43.82
Earnings Date	Feb 14, 2026

About Zydus Lifesciences

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pi...

• Industry: Pharmaceutical Preparations
• Founded: 1952
• Employees: 27,917
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532321

Financial Performance

In 2024, Zydus Lifesciences's revenue was 232.42 billion, an increase of 18.90% compared to the previous year's 195.47 billion. Earnings were 45.26 billion, an increase of 17.26%.